LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Rhythm Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

59.97 -0.27

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

58.84

Massimo

60.78

Metriche Chiave

By Trading Economics

Entrata

-6.2M

-49M

Vendite

-9.1M

33M

EPS

-0.81

Margine di Profitto

-151.352

Dipendenti

283

EBITDA

-9.5M

-47M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+43.3% upside

Dividendi

By Dow Jones

Utili prossimi

5 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-319M

3.8B

Apertura precedente

60.24

Chiusura precedente

59.97

Notizie sul Sentiment di mercato

By Acuity

50%

50%

177 / 382 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

Rhythm Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

16 mag 2025, 19:39 UTC

I principali Market Mover

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

16 mag 2025, 23:18 UTC

Notizie principali

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16 mag 2025, 22:30 UTC

Notizie principali

U.S. Loses Last Triple-A Credit Rating -- Update

16 mag 2025, 21:56 UTC

Discorsi di Mercato

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16 mag 2025, 21:56 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

16 mag 2025, 21:54 UTC

Notizie principali

U.S. Loses Last Triple-A Credit Rating -- WSJ

16 mag 2025, 21:22 UTC

Discorsi di Mercato

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16 mag 2025, 21:17 UTC

Discorsi di Mercato

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16 mag 2025, 21:17 UTC

Notizie principali

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16 mag 2025, 21:05 UTC

Discorsi di Mercato

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16 mag 2025, 20:55 UTC

Acquisizioni, Fusioni, Takeovers

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 mag 2025, 20:50 UTC

Discorsi di Mercato
Utili

Financial Services Roundup: Market Talk

16 mag 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

16 mag 2025, 20:37 UTC

Notizie principali

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16 mag 2025, 20:33 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16 mag 2025, 20:30 UTC

Acquisizioni, Fusioni, Takeovers

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16 mag 2025, 20:18 UTC

Notizie principali

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16 mag 2025, 20:16 UTC

Notizie principali

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16 mag 2025, 20:15 UTC

Utili

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16 mag 2025, 20:11 UTC

Acquisizioni, Fusioni, Takeovers

Henry Schein: William K. Daniel Joins Board

16 mag 2025, 20:10 UTC

Acquisizioni, Fusioni, Takeovers

Henry Schein: Strategic Investment by KKR Completed

16 mag 2025, 20:05 UTC

Acquisizioni, Fusioni, Takeovers

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 mag 2025, 19:38 UTC

Discorsi di Mercato

Oil Futures Post Second Straight Weekly Gain -- Market Talk

16 mag 2025, 19:07 UTC

Discorsi di Mercato

U.S. Natural Gas Futures End Week Lower -- Market Talk

16 mag 2025, 18:51 UTC

Notizie principali

Early Read on Consumer Sentiment Falls to Second Lowest on Record -- 5th Update

16 mag 2025, 18:41 UTC

Acquisizioni, Fusioni, Takeovers

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 mag 2025, 18:37 UTC

Discorsi di Mercato

Gold Futures End Week on Negative Note -- Market Talk

16 mag 2025, 18:35 UTC

Notizie principali

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

16 mag 2025, 18:32 UTC

Notizie principali

Trump Floats Plan to Impose New Tariff Rates; Stocks Hold Steady -- WSJ

16 mag 2025, 18:28 UTC

Discorsi di Mercato

Weaker Dollar Seen as Helping Some Business to Avoid Price Increases -- Market Talk

Confronto tra pari

Modifica del prezzo

Rhythm Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

43.3% in crescita

Previsioni per 12 mesi

Media 82.08 USD  43.3%

Alto 94 USD

Basso 72 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Rhythm Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

12

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

60 / 65.58Supporto e resistenza

A breve termine

Strong Bearish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

177 / 382 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.